Sign Out
FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available: Hypersensitivity to the product.
Disseminated intravascular Coagulation (DIC): Laboratory and/or clinical symptoms which are clearly indicative of DIC.
Laboratory, histological and/or clinical signs of liver damage; due to the delayed clearance of activated coagulation factors such patients are at an increased risk of developing DIC.
Myocardial infarction, Acute Thrombosis and/or Embolism: In patients with a tentative or definite diagnosis of coronary heart disease as well as in patients with acute thrombosis and/or embolism the use of FEIBA is only indicated in life-threatening bleeding episodes.
Continue with Google